BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the…
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on…
The Perfect Beer for Toasting The Trail Less TraveledLITTLETON, Colo., April 29, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery (“Breck Brew”)…
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted…
First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine’s Ex Vivo Product Candidate Designed to Correct a Prevalent…
EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop…
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2024…
TORONTO, April 29, 2024 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQX: DOCRF, Frankfurt: 6PH) (the “Company”…
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients…
Vaughan, Ontario--(Newsfile Corp. - April 29, 2024) - Delota Corp. (CSE: NIC) (FSE: S62) ("Delota" or the "Company") a leading…